How much of scpharmaceuticals stock are insiders buying?
In the past three months, scPharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $59,150.00 in company stock and sold $0.00 in company stock. Only 3.71% of the stock of scPharmaceuticals is held by insiders. 58.64% of the stock of scPharmaceuticals is held by institutions.
What does Schwarz Pharma do?
Schwarz Pharma, Inc. was founded in 2009. The Company's line of business includes the manufacturing, fabricating, and processing of drugs in pharmaceutical preparations for human and veterinary use. NO. OF EMPLOYEES
Where can I buy shares of SCPH?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What does scpharmaceuticals's P/E ratio and P/B ratio indicate?
The P/E ratio of scPharmaceuticals is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. scPharmaceuticals has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Should I buy or sell scPharmaceuticals stock right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 1 hold rating and...
What is scPharmaceuticals' stock price forecast for 2022?
2 Wall Street analysts have issued twelve-month price objectives for scPharmaceuticals' stock. Their forecasts range from $6.00 to $15.00. On avera...
How has scPharmaceuticals' stock performed in 2022?
scPharmaceuticals' stock was trading at $5.02 on January 1st, 2022. Since then, SCPH stock has decreased by 2.4% and is now trading at $4.90. View...
When is scPharmaceuticals' next earnings date?
scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for...
How were scPharmaceuticals' earnings last quarter?
scPharmaceuticals Inc. (NASDAQ:SCPH) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.28) earnings per share (E...
Who are scPharmaceuticals' key executives?
scPharmaceuticals' management team includes the following people: Mr. John H. Tucker , Pres, CEO, Principal Exec. Officer, Principal Financial Of...
Who are some of scPharmaceuticals' key competitors?
Some companies that are related to scPharmaceuticals include Zealand Pharma A/S (ZEAL) , Y-mAbs Therapeutics (YMAB) , Atai Life Sciences (ATAI)...
What other stocks do shareholders of scPharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuti...
When did scPharmaceuticals IPO?
(SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 p...
What is the increase in expenses for scpharmaceuticals?
scPharmaceuticals reported a net loss of $32.2 million for the year ended December 31, 2020, compared to $33.0 million for the comparable period in 2019.
What is scpharmaceuticals 2021?
(Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 EDT. A live webcast of the presentation can be accessed under “News and Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. About scPharmaceuticals scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com. Katherine TaudvinscPharmaceuticals Inc., [email protected] Investors:Hans VitzthumLifeSci Advisors, [email protected]
What is SCPH 2021?
(Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 11:20 EDT. A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. About scPharmaceuticals scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com. Katherine TaudvinscPharmaceuticals Inc., [email protected] Investors:Hans VitzthumLifeSci Advisors, [email protected]
When will Furoscix be resubmitted?
FDA and Company in alignment on the path forward No additional clinical data or device modifications required at this time FUROSCIX NDA resubmission targeted for Q4 2021 BURLINGTON, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that on June 30, 2021 th
How much will scpharmaceuticals lose in 2021?
scPharmaceuticals reported a net loss of $7.1 million for the first quarter of 2021, compared to $7.1 million for the comparable period in 2020.
Does the FDA require modifications to Furoscix?
ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional clinical studies to demonstrate the safety and efficacy of Furoscix.
About scPharmaceuticals
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting.
scPharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" scPharmaceuticals stock. View analyst ratings for scPharmaceuticals or view top-rated stocks.
Wall Street gyrations may thwart deal closings, IPO outlook
In terms of doing mergers and acquisitions and raising money through initial public offerings, 2021 was huge. But 2022 may be vastly different.
CinCor Pharma Appoints June Lee to Its Board of Directors
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry and has served in numerous executive and board roles.
10 Best Stocks to Buy on the Nasdaq Right Now
When you’re looking for stocks to buy there are so many things you can take into account, but starting with looking at the markets themselves is a good tactic. With such a blistering performance in the benchmark indices throughout most of the post-pandemic months, it may have been inevitable that a correction would occur.
2.5 Analyst's Opinion
CinCor Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Is CinCor Pharma a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CinCor Pharma in the last twelve months. There are currently 4 buy ratings for the stock.
What price target have analysts set for CINC?
4 analysts have issued 1-year price objectives for CinCor Pharma's shares. Their forecasts range from $27.00 to $30.00. On average, they expect CinCor Pharma's share price to reach $29.00 in the next twelve months.
Who are some of CinCor Pharma's key competitors?
Some companies that are related to CinCor Pharma include Canopy Growth (CGC), Cano Health (CANO), BioCryst Pharmaceuticals (BCRX), Karuna Therapeutics (KRTX), Merit Medical Systems (MMSI), Life Time Group (LTH), Apollo Medical (AMEH), BTG (BTG), National Vision (EYE), CureVac (CVAC), Select Medical (SEM), Owens & Minor (OMI), Cytokinetics (CYTK), Twist Bioscience (TWST) and AtriCure (ATRC). View all of CINC's competitors..
When does CinCor Pharma's quiet period expire?
CinCor Pharma's quiet period expires on Wednesday, February 16th. CinCor Pharma had issued 12,100,000 shares in its public offering on January 7th. The total size of the offering was $193,600,000 based on an initial share price of $16.00.
How do I buy shares of CinCor Pharma?
Shares of CINC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is CinCor Pharma's stock price today?
One share of CINC stock can currently be purchased for approximately $23.56.
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
Vincerx Pharma Inc
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
Details
Schwarz Pharma brings three exciting, approved and late stage new compounds, complementary therapeutic and geographic focus, strong talent and cultural fit.
M&A Details
Schwarz Pharma AG was acquired by UCB for €4.4M on Sep 25, 2006. This deal was done in Cash.
